Medivir

1,39

SEK

-2,11 %

Mindre end 1K følgere

MVIR

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

-2,11%

-26,46%

-51,06%

-50,18%

-52,4%

-49,38%

-78,63%

-83,15%

-97,63%

Medivir is a pharmaceutical company focused on developing innovative treatments for cancer and infectious diseases. The company is researching new therapies that can improve patient outcomes and quality of life. The company operates globally with a primary presence in Europe and North America. Medivir was founded in 1991 and is headquartered in Stockholm, Sweden.

Markedsværdi

159,32 mio. SEK

Aktieomsætning

1,14 mio. SEK

Omsætning

3,5 mio.

EBIT %

-3.637,14 %

P/E

-

Udbytteafkast, %

-

Finanskalender

29.4

2025

Delårsrapport Q1'25

7.5

2025

Generalforsamling '25

21.8

2025

Delårsrapport Q2'25

Alle

Selskabspræsentationer

Selskabsmeddelelser

ViserAlle indholdstyper

Pressemeddelelse20.3.2025, 07.41

Medivir comments on the patent approval

Pressemeddelelse19.3.2025, 08.15

Medivir receives European patent for fostrox plus lenvatinib in treatment of hepatocellular carcinoma (HCC) and cancer metastases in the liver

Pressemeddelelse13.3.2025, 17.05

Carnegie Access: Medivir: Highlights from Carnegie’s Healthcare Conference

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Pressemeddelelse13.3.2025, 07.45

Medivir to present at the Carnegie Healthcare Day

Pressemeddelelse7.3.2025, 07.40

Medivir's CEO to BioStock: "I am proud to see our research contribute to a global solution"

Pressemeddelelse25.2.2025, 09.30

Medivir’s partner Infex Therapeutics signs a license agreement for the clinical development of MET-X in India

Pressemeddelelse21.2.2025, 09.38

BioStock: Medivir's investigator on the positive results directly from EASL

Pressemeddelelse20.2.2025, 09.46

Carnegie Access: Medivir: Final study results presented at EASL

Pressemeddelelse20.2.2025, 08.00

Medivir presents positive final phase 1b/2a fostrox + Lenvima data in advanced liver cancer at EASL Liver Cancer Summit

Pressemeddelelse19.2.2025, 10.32

Carnegie Access: Medivir: Financing uncertainty still tops the agenda – Q4(24) review

Pressemeddelelse19.2.2025, 06.36

Redeye: Medivir Q4 2024 - Phase IIb Trial Design Set

Pressemeddelelse18.2.2025, 13.05

Medivir's CEO: "We have attracted interest from the best investigators and hospitals to be part of the phase IIb study"

Medivir, Audiocast with teleconference, Q4'24

Videopræsentation18.2.2025, 13.00

Medivir, Audiocast with teleconference, Q4'24

Selskabsmeddelelse18.2.2025, 07.30

MEDIVIR AB – YEAR-END REPORT JANUARY – DECEMBER 2024

Pressemeddelelse2.2.2025, 15.20

Anders Hallberg transfers his ownership to occupational pension insurance

Pressemeddelelse22.1.2025, 11.00

Medivir to present at the Redeye Fight Cancer Event

Pressemeddelelse23.12.2024, 12.05

BioStock: Medivir to highlight promising clinical data at EASL

Pressemeddelelse19.12.2024, 07.30

Medivir to present final safety and efficacy data for fostrox + Lenvima in advanced liver cancer at EASL Liver Cancer Summit

Pressemeddelelse16.12.2024, 10.07

Medivir's CEO to BioStock: "The IND approval is a very important milestone"

Pressemeddelelse16.12.2024, 07.30

Medivir obtains IND approval for fostrox - the first oral, liver-targeted treatment for advanced liver cancer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.